Core Viewpoint - Recently, Jiangsu Hengrui Medicine Co., Ltd. and its subsidiaries received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in their drug development pipeline [1] Group 1: Clinical Trial Approvals - The company has received approval for clinical trials of HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Abediteran injection, Bevacizumab injection, SHR-A2102 injection, Apalutamide capsules, and Darsylis sulfate tablets [1] - The approval is based on compliance with the relevant drug registration requirements as per the Drug Administration Law of the People's Republic of China [1] - The specific study includes a Phase I/II trial to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with anti-tumor drugs in subjects with solid tumors [1]